Dr. Gu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
UT Southwestern
Dallas, TX 75390- Is this information wrong?
Summary
- Dr. Phillip Gu is a gastroenterologist in Dallas, TX. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 1 year. He specializes in inflammatory bowel disease and is experienced in endoscopy, colonoscopy, and gastreoenterology.
Education & Training
- University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 2018 - 2021
- University of Texas Southwestern Medical CenterFellowship, Gastroenterology, 2021
- University of Texas Southwestern Medical CenterGastroenterology, 2021
- Cedars-Sinai Medical CenterResidency, Internal Medicine, 2015 - 2018
- University of Texas Southwestern Medical SchoolClass of 2015
Certifications & Licensure
- CA State Medical License 2017 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Publications & Presentations
PubMed
- Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn's disease.Phillip Gu, Shishir Dube, Norman Gellada, So Yung Choi, Susan Win, Yoo Jin Lee, Shaohong Yang, Talin Haritunians, Gil Y Melmed, Eric A Vasiliauskas, Niru Bonthala, Gau...> ;World Journal of Gastrointestinal Surgery. 2024 Mar 27
- Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD).Phillip Gu, Shishir Dube, YooJin Lee, Shaohong Yang, Dalin Li, Talin Haritunians, Eric Vasiliauskas, Niru Bonthala, Gaurav Syal, Andres Yarur, David Ziring, Stephan Ta...> ;Digestive Diseases and Sciences. 2024 Jan 1
- 4 citationsPatients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve Remission.Andres J Yarur, Maria T Abreu, Parakkal Deepak, Poonam Beniwal-Patel, Konstantinos Papamichael, Byron Vaughn, Alexandra Bruss, Shaina Sekhri, Andrea Moosreiner, Philli...> ;The American Journal of Gastroenterology. 2023 Nov 1
- Join now to see all
Press Mentions
- Obesity May Not Affect Unplanned Health Care Utilization, Safety of Therapy in IBDMay 28th, 2022
Hospital Affiliations
- Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: